ReviewAmerican journal of obstetrics and gynecology2022
Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.
Review in American journal of obstetrics and gynecology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 6 syntheses or guidelines pooled it, 296 citations in OpenAlex.
- Association between multiple pregnancy with peripartum cardiomyopathy: a systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Investigating the association of albuminuria with the incidence of preeclampsia and its predictive capabilities: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2025Pooled it
- Associations between adverse pregnancy outcomes and cognitive impairment and dementia: a systematic review and meta-analysis.The lancet. Healthy longevity · 2024Pooled it
- Influential Serum Kinases (Non-sFlt-1) and Phosphatases in Preeclampsia-Systemic Review and Metanalysis.International journal of molecular sciences · 2023Pooled it
- SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis.American journal of obstetrics and gynecology · 2022Pooled it
- Predictive Performance of Placental Protein 13 for Screening Preeclampsia in the First Trimester: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.American journal of obstetrics and gynecology · 2021Trial
- Understanding physiological adaptations of pregnancy to the chronic hypoxia of high altitude to inform obstetrical and neonatal care.Physiological reviews · 2026Review
- Expression patterns of circulating microRNA in confirmed early-onset and late-onset pre-eclampsia cases.Archives of gynecology and obstetrics · 2026Article
- Modulation of oxidative stress and angiogenic pathways by natural compounds in experimental preeclampsia: A narrative review focusing on MDA, sFlt-1, and PlGF.Turkish journal of obstetrics and gynecology · 2026Article
- The endothelin-1/TLR4/NF-κB/NLRP3 inflammasome axis in preeclampsia: a review of a pathological feed-forward loop and therapeutic frontier.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Cardiac Biomarkers and Pregnancy-Associated Cardiovascular Disease.Current cardiology reports · 2026Review
- Association Between Maternal Angiogenic Markers in Hypertensive Disorders of Pregnancy and Neonatal Growth and Body Composition.Nutrients · 2026Article
- Preeclampsia Screening.Diagnostics (Basel, Switzerland) · 2026Review
- Acute Left Heart Failure in Twin Pregnancies: Clinical Characteristics and Outcomes-A 10‑Year Retrospective Analysis of 24 Cases.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Dialysis and Pregnancy: Optimizing Therapy for Best Maternal and Fetal Outcomes.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Review
- Large-scale proteomics in early pregnancy and timing of onset of hypertensive disorders of pregnancy.medRxiv : the preprint server for health sciences · 2026Article
- Concordant and Discordant Transcriptomic Signatures of Twin Placentas in the Setting of Preeclampsia.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Systemic Immune-Inflammation Index as a Predictive Biomarker for Pre-Eclampsia.Journal of clinical medicine · 2026Review
- Transcription factor IRF1 modulates HDAC1 and PANoptosis to regulate preeclampsia progression.Biology direct · 2026Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is a devastating medical complication of pregnancy that can lead to significant maternal and fetal morbidity and mortality. It is currently believed that there is abnormal placentation in as early as the first trimester in women destined to develop preeclampsia. Although the etiology of the abnormal placentation is being debated, numerous epidemiologic and experimental studies suggest that imbalances in circulating angiogenic factors released from the placenta are responsible for the maternal signs and symptoms of preeclampsia. In particular, circulating levels of soluble fms-like tyrosine kinase 1, an antiangiogenic factor, are markedly increased in women with preeclampsia, whereas free levels of its ligand, placental, growth factor are markedly diminished. Alterations in these angiogenic factors precede the onset of clinical signs of preeclampsia and correlate with disease severity. Recently, the availability of automated assays for the measurement of angiogenic biomarkers in the plasma, serum, and urine has helped investigators worldwide to demonstrate a key role for these factors in the clinical diagnosis and prediction of preeclampsia. Numerous studies have reported that circulating angiogenic biomarkers have a very high negative predictive value to rule out clinical disease among women with suspected preeclampsia. These blood-based biomarkers have provided a valuable tool to clinicians to accelerate the time to clinical diagnosis and minimize maternal adverse outcomes in women with preeclampsia. Angiogenic biomarkers have also been useful to elucidate the pathogenesis of related disorders of abnormal placentation such as intrauterine growth restriction, intrauterine fetal death, twin-to-twin transfusion syndrome, and fetal hydrops. In summary, the discovery and characterization of angiogenic proteins of placental origin have provided clinicians a noninvasive blood-based tool to monitor placental function and health and for early detection of disorders of placentation. Uncovering the mechanisms of altered angiogenic factors in preeclampsia and related disorders of placentation may provide insights into novel preventive and therapeutic options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.